Telaglenastat
Tumors Harboring Isocitrate Dehydrogenase-1 (IDH1) and IDH2 Mutations
Calithera Biosciences, IncSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Tumors Harboring Isocitrate Dehydrogenase-1 (IDH1) and IDH2 Mutations cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Bms-907351 Calithera Biosciences, Inc | Phase 1 | CC |
Cbe Calithera Biosciences, Inc | Phase 1 | CC |
Same molecule, other indications
Telaglenastat is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →